Menu
Search
|

Menu

Close
X

Orgenesis Inc ORGS.OQ (NASDAQ Stock Exchange Capital Market)

6.82 USD
-0.08 (-1.16%)
As of 1:30 AM IST
chart
Previous Close 6.90
Open 6.87
Volume 2,998
3m Avg Volume 8,975
Today’s High 6.89
Today’s Low 6.77
52 Week High 16.34
52 Week Low 6.02
Shares Outstanding (mil) 121.14
Market Capitalization (mil) 54.51
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
10
FY16
6
FY15
3
EPS (USD)
FY18
-0.720
FY17
-1.192
FY16
-1.390
FY15
-0.959
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
6.90
5.75
Price to Book (MRQ)
vs sector
5.41
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
77.40
16.85
LT Debt to Equity (MRQ)
vs sector
51.08
12.51
Return on Investment (TTM)
vs sector
-71.05
14.61
Return on Equity (TTM)
vs sector
-118.65
16.33

EXECUTIVE LEADERSHIP

Vered Caplan
Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc., Since 2016
Salary: $185,596.00
Bonus: --
Neil Reithinger
Chief Financial Officer, Treasurer, Secretary, Since 2014
Salary: $6,000.00
Bonus: --
Sarah Ferber
Chief Scientific Officer, Since 2012
Salary: $286,160.00
Bonus: --
Yaron Adler
Director, Since 2012
Salary: --
Bonus: --
David Sidransky
Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

20271 Goldenrod Ln
GERMANTOWN   MD   20876-4064

Phone: +1480.6596404

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

SPONSORED STORIES